公开(公告)号：US11649281B2

公开(公告)日：2023-05-16

申请号：US16555524

申请日：2019-08-29

Applicant: NB Health Laboratory Co., Ltd.

Inventor： Kiyoshi Takayama ,  Tomoko Shimizu ,  Yuji Urushibata ,  Yukihiko Sugimoto

IPC: C07K16/28 ,  C07K17/00 ,  G01N33/88

CPC classification number: C07K16/28 ,  C07K16/2869 ,  C07K17/00 ,  G01N33/88 ,  C07K2317/24 ,  C07K2317/76

Abstract: It is an object of the present invention to provide an antibody that binds to a human PGE2 receptor subtype EP4 and inhibits the function of EP4, or a functional fragment thereof. It is another object of the present invention to provide a medicament comprising the aforementioned antibody or a functional fragment thereof. Mice were immunized with the human PGE2 receptor subtype EP4, and a monoclonal antibody that suppresses the intracellular cAMP level increase induced by EP4 was screened. In addition, the CDR sequences of the obtained monoclonal antibody were determined.

公开(公告)号：US20220211899A1

公开(公告)日：2022-07-07

申请号：US17600636

申请日：2020-03-03

Applicant: HITACHI, LTD. ,  TOKYO INSTITUTE OF TECHNOLOGY

Inventor： Tomio IWASAKI ,  Masashi MARUYAMA ,  Takeshi SERIZAWA ,  Toshiki SAWADA

IPC: A61L15/58 ,  A61L15/24 ,  A61L15/44 ,  A61L27/16 ,  A61L27/28 ,  A61L27/54 ,  A61L29/04 ,  A61L29/08 ,  A61L29/16 ,  A61L31/04 ,  A61L31/08 ,  A61L31/16 ,  C07K17/00 ,  C07K7/06 ,  C07K7/08

Abstract: The present invention provides a biocompatible material improved in biocompatibility owing to adsorption of a peptide that has high adhesion with a resin and hardly separates from a surface of the resin, and a functional material including the biocompatible material. The biocompatible material includes a resin and a peptide adsorbed on the resin. The resin has methoxycarbonyl groups and methyl groups, and tryptophan or arginine accounts for 70% or more of amino acid residues in the peptide. As an alternative, the resin is a fluorinated resin, and 2,3,4,5,6-pentafluoro-phenylalanine, 3-(trifluoromethyl)alanine, serine, threonine, histidine, aspartic acid, glutamic acid, phenylalanine, or aspartic acid accounts for 40% or more of the amino acid residues in the peptide. The functional material includes the biocompatible material, and a functional substance. The functional substance is held on a surface of the biocompatible material or is released from the surface of the biocompatible material.

公开(公告)号：US11312756B2

公开(公告)日：2022-04-26

申请号：US16402754

申请日：2019-05-03

Applicant: The Trustees of Princeton University

Inventor： A. James Link ,  Siyan Zhang

IPC: A61K38/10 ,  A61K38/00 ,  A61P35/00 ,  A61K38/04 ,  C07K5/00 ,  C07K7/00 ,  C07K17/00 ,  C07K14/47 ,  C07K7/08 ,  A61K38/12 ,  A61K38/17 ,  A61K31/635 ,  G01N33/50 ,  G01N33/68

Abstract: Compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. Pharmaceutical compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. A method for treating cancer is provided.

公开(公告)号：US11300574B2

公开(公告)日：2022-04-12

申请号：US15990172

申请日：2018-05-25

Applicant: UNIVERSITY OF CONNECTICUT

Inventor： David Han ,  Veneta Qendro

IPC: G01N33/68 ,  C07K14/47 ,  G01N33/574 ,  C07K4/00 ,  C07K4/12 ,  C07K17/00 ,  C07K1/13 ,  C07K17/02 ,  C07K17/14

Abstract: Disclosed herein are isolated compositions including at least 2 of mutant peptides selected from the group consisting of SEQ ID NOS: 1-149, or polypeptides comprising the mutant peptides; wherein the composition comprises mutant peptides encoded by 2 or more genes. Also disclosed are methods for personalized treatment of breast cancer involving creating a peptide array of mutant peptides comprising the mutations in protein-encoding regions of the high-frequency cancer genes or the exome in a subject and screening the peptide array with a biological sample from the subject to detect antibodies in the biological sample that bind to the array, to detect antigenic targets for therapy in treating the subject.

公开(公告)号：US11274139B2

公开(公告)日：2022-03-15

申请号：US14784015

申请日：2014-04-10

Applicant: Evox Therapeutics Ltd.

Inventor： Samir El Andaloussi ,  Oscar Wiklander ,  Joel Nordin ,  Edvard Smith ,  Karl-Henrik Grinnemo ,  Oscar Simonson

IPC: A61K9/00 ,  A61K38/00 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00 ,  C07K1/00 ,  C07K14/705 ,  F01C21/10 ,  F01C1/344 ,  A61K47/69 ,  A61K47/62 ,  A61K38/17

Abstract: The present invention pertains to inter alia therapeutic delivery vesicles, for instance exosomes or microvesicles, comprising polypeptide constructs, methods for producing said therapeutic delivery vesicles, pharmaceutical compositions and medical uses thereof. The therapeutic polypeptide constructs comprised in the extracellular delivery vesicles enable sequestering target molecules of interest, to treat e.g. neuro-inflammatory diseases and cancer.

公开(公告)号：US11230576B2

公开(公告)日：2022-01-25

申请号：US16324651

申请日：2017-08-07

Applicant: Navigo Proteins GmbH

Inventor： Paul Knick ,  Erik Fiedler ,  Ulrich Haupts ,  Maren Meysing

IPC: C07K1/22 ,  C07K16/06 ,  C07K14/31 ,  C07K17/00

Abstract: The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

公开(公告)号：US11214600B2

公开(公告)日：2022-01-04

申请号：US16077213

申请日：2017-02-10

Applicant: The University of Chicago ,  Janssen Pharmaceuticals, Inc.

Inventor： Dominique Missiakas ,  Olaf Schneewind ,  Carla Emolo ,  Lena Thomer ,  Molly McAdow ,  Jeroen Geurtsen ,  Mark De Been

IPC: A61K39/02 ,  A61K39/00 ,  A61K45/00 ,  A61K47/00 ,  A61K39/085 ,  A61K38/00 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00 ,  C07K14/31 ,  C07K16/12 ,  C07K16/40 ,  C12Q1/689 ,  A61K39/40

Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa). Further aspects relate to immunogenic compositions comprising at least one Staphylococcal coagulase R Domain, wherein the R Domain is 80% identical in sequence to a R Domain.

公开(公告)号：US20210291143A1

公开(公告)日：2021-09-23

申请号：US17107600

申请日：2020-11-30

Applicant: Cytiva Bioprocess R&D AB

Inventor： Martin HALL ,  Sture LARSSON ,  Andreas MURANYI ,  Gustav RODRIGO ,  Jinyu ZOU ,  Per-Mikael ABERG

IPC: B01J20/24 ,  B01D15/38 ,  B01J20/286 ,  C07K1/22 ,  B01J20/32 ,  C07K14/31 ,  C07K16/00 ,  C07K17/00 ,  B01J20/28 ,  B01J20/285 ,  B01J20/289 ,  C07K17/10

Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

公开(公告)号：US11123400B2

公开(公告)日：2021-09-21

申请号：US15761089

申请日：2016-09-19

Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Jaehoon Yu ,  Yan Lee ,  Soonsil Hyun ,  Seo Yeon Kim ,  Sun Mi Jin ,  Yunhwa Choi ,  Doyeon Jo ,  Seonju Lee

IPC: A61K38/10 ,  A01N37/18 ,  A61K38/04 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  A61K38/16 ,  C07K7/08 ,  A61K31/616 ,  A61K31/431 ,  A61K31/192 ,  A61K31/05 ,  A61K31/12 ,  A61K31/5377 ,  A61K31/366 ,  A61P31/04 ,  A61P29/00 ,  A61P9/00 ,  A61K38/06 ,  A61K38/00 ,  A61K47/64

Abstract: The present invention relates to a broken or kinked helical peptide or peptide analogue and the use thereof, and more particularly to a Gram-negative bacterial membrane-penetrating peptide or peptide analogue wherein an alpha-helical amphipathic peptide composed of hydrophobic amino acids and hydrophilic amino acids has a kinked structure, or an antimicrobial composition employing the specific activity of the peptide against the Gram-negative bacterial membrane, or an antimicrobial composition for co-administration, or a conjugate comprising a drug linked to the peptide or peptide analogue, or an antibiotic comprising the same.

公开(公告)号：US11059874B2

公开(公告)日：2021-07-13

申请号：US16892577

申请日：2020-06-04

Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Michael Super ,  Jeffrey Charles Way ,  Donald E. Ingber

IPC: C07K14/47 ,  G01N33/569 ,  C07K16/44 ,  C07K17/00 ,  G01N33/50 ,  G01N27/74

Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.